Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

Condition:   Hypereosinophilic Syndrome
Interventions:   Drug: Mepolizumab 300 mg;   Drug: Placebo matching mepolizumab;   Drug: Active OCS capsules (5 mg prednisolone or prednisone);   Drug: Placebo matching OCS capsules
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified July 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days